Quantum Genomics Secures Financing, Avoids Liquidation

Quantum Genomics has announced the signing of a financing agreement with Akkadian Partners Fund. The agreement allows the company to avoid compulsory liquidation thanks to an advance of 500,000 euros.

This cash injection will allow the company to meet its financial needs for the next three months. During this period, Quantum Genomics plans to find additional financing and implement a growth strategy.

The agreement also provides for an overhaul of the company's governance. The current directors, including the Chairman and CEO, have resigned. Three new directors have been appointed, including Mathieu Bigois, now Chairman and CEO.

Quantum Genomics subsidiary Exactcure has filed its application for liquidation before the Paris Commercial Court. This procedure will have to be continued in Nice, where Exactcure is headquartered.